Be sure to inject into the soft, fatty tissue between the shoulder and elbow rather than the muscle
Shmerling (2024)
In the ATTAIN-2 trial (participants with obesity and type 2 diabetes), GI adverse event rates were somewhat higher than in ATTAIN-1: nausea 20.1-36.4% versus 8.4% with placebo, vomiting 12.8-23.1% versus 3.8%, diarrhea 21.3-27.4% versus 15.0%, and constipation 17.7-22.4% versus 7.8%
You can stay on GLP-1 medications long-term
Temperature consistency matters more than most patients realize
In the present study, we used only male mice to minimize variability introduced by the estrous cycle in females, which is known to influence toxicity, body weight, food intake, and metabolic parameters [31,32,33,34,35,36]